L
Description
Clinical-stage biopharmaceutical company founded in 2009 in Salt Lake City, Utah. Listed on NASDAQ (LPCN). Pioneer in oral delivery technologies for lipophilic compounds, focused on testosterone, CNS and liver diseases. Candidate LPCN 1154 completed Phase 3 enrollment for postpartum depression in January 2026.